Anika Therapeutics Inc. EV/FCF

EV/FCF of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/FCF of Anika Therapeutics Inc. is 46.74 (as of December 30, 2020)
  • EV/FCF for the quarter ending September 29, 2021 was 157.91 (a 144.46% increase compared to previous quarter)
  • Year-over-year quarterly EV/FCF increased by 237.86%
  • Annual EV/FCF for 2020 was 46.74 (a 180.37% increase from previous year)
  • Annual EV/FCF for 2019 was 16.67 (a 53.76% increase from previous year)
  • Annual EV/FCF for 2018 was 10.84 (a -46.48% decrease from previous year)
Visit stockrow.com/ANIK for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Anika Therapeutics Inc.

Most recent EV/FCFof ANIK including historical data for past 10 years.

Interactive Chart of EV/FCF of Anika Therapeutics Inc.

Anika Therapeutics Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 157.91 64.59 54.44
2020 46.74 18.78 16.99 12.62 46.74
2019 16.67 19.9 14.23 9.41 16.67
2018 10.84 17.97 13.93 21.8 10.84
2017 20.26 22.08 18.63 21.97 20.26
2016 58.72 39.55 47.96 19.28 58.72
2015 14.11 9.69 10.66 17.45 14.11
2014 12.82 14.41 18.7 16.24 12.82
2013 19.37 12.3 11.48 8.98 19.37
2012 10.76 15.08 14.23 26.81 10.76
2011 11.06 11.09 16.71 13.77 11.06
2010 0.0 0.0

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.